Follow the sources behind these NAD+ questions
These links are here to help you check a claim. Each source has a job, and none answers every question about a preparation.
Biology and oral studies
The NAD+ biology review from Covarrubias and colleagues explains NAD+ biology and its role in cells. Published in 2021, it gives background for the interest in NAD+. A biological role doesn't establish a treatment benefit.
The 2019 NR trial by Conze and colleagues tested swallowed nicotinamide riboside in healthy overweight adults. It's used here for increased blood NAD+ and the comparison of reported health problems with placebo, a dummy comparison treatment. Those findings don't establish long-term safety or the benefits of an injection.
The 2021 NMN study by Yoshino and colleagues tested nicotinamide mononucleotide in postmenopausal women with prediabetes. Muscle became more responsive to insulin; body composition (the mix of fat and other tissue) and HbA1c, a longer-term blood-sugar measure, didn't change. Both sides of that result matter.
The 2025 human ageing review from Vinten and colleagues looks across precursor studies. It finds limited evidence of health benefits and sparse measurements inside particular human tissues. It's a useful check on broad promises.
Cells and infusions
The skin-cell experiment by Aleo and colleagues examined what happened to NAD outside cultured human cells. This 2001 laboratory study found NAD breaking down outside the cells, which took up adenosine, a breakdown product. It wasn't a treatment study in people.
The 2019 IV NAD+ pilot study followed changes in blood and urine during an infusion. It helps describe how the body handled the substance. It doesn't establish lasting improvements in energy, thinking or lifespan.
These sources sit on the IV page. Neither turns the results of an oral precursor study into evidence for an infusion.
Quality, reporting and access
FDA's guide to compounded-drug risks explains the lack of FDA approval and risks such as contamination. It supports the general quality discussion, rather than documenting the specific NAD+ recall mentioned on the safety page.
FDA's compounding questions and answers explain how compounded medicines differ from approved drugs. An individual prescription doesn't erase that distinction.
The FDA Adverse Event Monitoring System dashboard page explains the limits of reports. They don't establish cause or tell us how often a problem occurs.
FDA's MedWatch programme is a place to report safety concerns. It isn't a substitute for care.
Where you are during an online visit matters to licensing; HHS's telehealth guide explains the connection. It doesn't establish access to every treatment in every state.
Follow the link, then check what it can tell you.